AMIA Comments on FDA Mobile Medical Apps Draft Guidance

AMIA recently issued comments in response to a U.S. Food and Drug Administration (FDA) draft guidance on mobile medical applications. In the comments, AMIA president Ted Shortliffe noted, among other things, the need for additional clarification, definitions, terms, and terminology in the guidance. Click below to read AMIA's full comments.